louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03192774: The Prospective Segeberg TAVI Registry
Official title: A Prospective Follow-up Assessment of Transcatheter Aortic Valve Implantation in Bad Segeberg
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Aortic Valve Stenosis
Lead sponsor: Segeberger Kliniken GmbH
Sponsor class: OTHER
First posted: 2017-06-20
Enrollment: 2000
Sex: ALL
Minimum age (years): 18
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All comers patient population treated with TAVI.

Brief summary: A single center registry including all patients treated with TAVI at the Heart Center, Bad Segeberg, Germany

Detailed description: A prospective single center registry including all patients treated with transcatheter aortic valve implantation (TAVI) at the Heart Center, Bad Segeberg, Germany. Patients undergo a routine clinical and echocardiographic follow-up schedule, including a long-term follow-up plan beyond 5 years to assess valve durability.

Eligibility criteria: Inclusion Criteria:

* All patients treated with TAVI

Exclusion Criteria:

* None

Primary outcomes:
measure: Mortality
timeFrame: Up to 10 years
Secondary outcomes:
measure: Structural valve deterioration
timeFrame: Up to 10 years
Other outcomes:
Locations:
city: Bad Segeberg
country: Germany
facility: Heart Center, Segeberger Kliniken
Study officials:
affiliation: Heart Center, Segeberger Kliniken
name: Gert Richardt, MD
role: STUDY_CHAIR
affiliation: Heart Center, Segeberger Kliniken
name: Mohamed Abdel-Wahab, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Alotaibi S, Elbasha K, Landt M, Kaur J, Kurniadi A, Abdel-Wahab M, Toelg R, Richardt G, Allali A. Prognostic Value of HFA-PEFF Score in Patients Undergoing Transcatheter Aortic Valve Implantation. Cureus. 2022 Jul 22;14(7):e27152. doi: 10.7759/cureus.27152. eCollection 2022 Jul.
citation: Abdelghani M, Mankerious N, Landt M, Toelg R, Abdel-Wahab M, Richardt G. Transcatheter Aortic Valve Implantation With the Third Generation Balloon-Expandable Bioprosthesis in Patients With Severe Landing Zone Calcium. Am J Cardiol. 2020 Mar 15;125(6):931-940. doi: 10.1016/j.amjcard.2019.12.022. Epub 2019 Dec 27.
Clinical trial NCT04366674: Mordified Restoration of Tensor Veli Palatini in Cleft Palate Repair
Official title: The Possible Effect of Modified Restoration of Tensor Veli Palatini on Audiological and Otological Outcome in Cleft Palate Repair.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cleft Palate
Lead sponsor: Peking Union Medical College Hospital
Sponsor class: OTHER
First posted: 2020-04-29
Enrollment: 71
Sex: ALL
Minimum age (years): 6
Maximum age (years): 60
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: to study the benefical audiological and/or otological effect by mordified restoration of tensor veli palatini in cleft palate repair compared to traditional Langenbeck's repair and merely levator veli palatini restoration.

Detailed description: 71 patients with cleft palate received surgery were divided into 3 groups. Group 1: patients who received Langenbeck surgery without specific restoration of levator veli palatini or tensor veli palatini. Group 2: patients who received palate surgery with special levator veli palatini restoration. Group 3: patients who received palate surgery with modified tensor veli palatini restoration. The conductive auditory brainstem response and 226 Hz tympanometry were used to test the audiological and otological status of the three groups. Preoperative and postoperative results were compared intragroup and intergroup.

Eligibility criteria: Inclusion Criteria:

* Clinical diagnosis of cleft palate.
* Primary palate repair.

Exclusion Criteria:

* Severe general disease
* Confirmed hereditary hearing loss or neuropathic hearing loss.
* Received any kind of audiological or otological therapy before.
* Patients and/or his/her don't want to continue the clinical trial.

Primary outcomes:
measure: Hearing level
timeFrame: 3 months after surgery
measure: The otological status of middle ear
timeFrame: 3 months after surgery
measure: Hearing level
timeFrame: 0 to 3 months before surgery
measure: The otological status of middle ear
timeFrame: 0 to 3 months before surgery
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Peking Union Medical College Hospital
name: Lian Zhou, D.D.S
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02974374: Single Dose of PF-06835919 Escalation Study in Healthy Adult Subjects
Official title: A Phase 1, Randomized, Double-blind, Placebo-controlled Study To Assess Safety, Tolerability And Pharmacokinetics Of Single, Escalating, Oral Doses Of Pf-06835919 In Healthy Adult Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Non-alcoholic Fatty Liver Disease
Lead sponsor: Pfizer
Sponsor class: INDUSTRY
First posted: 2016-11-28
Enrollment: 16
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to assess the safety, tolerability, and pharmacokinetics of a single dose of PF-06835919 in healthy adult subjects.


Eligibility criteria: Inclusion Criteria:

* Healthy males and female of non-childbearing potential;
* Body Mass Index 21.5 to 30.5 kg/m2 (inclusive);
* Total body weight \>50 kg (110 lbs).

Exclusion Criteria:

-Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).

Primary outcomes:
measure: Number of Subjects experiencing an Adverse Event
timeFrame: Screening up to 28 days after last dose of study medication
Secondary outcomes:
measure: Maximum Observed Plasma Concentration (Cmax) for PF-06835919
timeFrame: 0, 0.33, 1, 2, 3, 4, 5, 6, 8,10, 12, 16, 24, and 48 hours post dose
measure: Time to Reach Maximum Observed Concentration for PF-06835919
timeFrame: 0, 0.33, 1, 2, 3, 4, 5, 6, 8,10, 12, 16, 24, and 48 hours post dose
measure: Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for PF-06835919
timeFrame: 0, 0.33, 1, 2, 3, 4, 5, 6, 8,10, 12, 16, 24, and 48 hours post dose
measure: Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0- infinity)] for PF-06835919
timeFrame: 0, 0.33, 1, 2, 3, 4, 5, 6, 8,10, 12, 16, 24, and 48 hours post dose
measure: Plasma Decay Half-Life (t1/2) for PF-06835919 (as permitted)
timeFrame: 0, 0.33, 1, 2, 3, 4, 5, 6, 8,10, 12, 16, 24, and 48 hours post dose
measure: Apparent Total Body Clearance (CL/F) for PF-06835919 (as permitted)
timeFrame: 0, 0.33, 1, 2, 3, 4, 5, 6, 8,10, 12, 16, 24, and 48 hours post dose
measure: Apparent Volume of Distribution (Vz/F) for PF-06835919 (as permitted)
timeFrame: 0, 0.33, 1, 2, 3, 4, 5, 6, 8,10, 12, 16, 24, and 48 hours post dose
Other outcomes:
Locations:
city: New Haven
country: United States
facility: Pfizer New Haven Clinical Research Unit
state: Connecticut
Study officials:
affiliation: Pfizer
name: Pfizer CT.gov Call Center
role: STUDY_DIRECTOR
References:
Clinical trial NCT00193674: Habitual Abortion Study: Oral Dydrogesterone Treatment During Pregnancy in Women With Recurrent Miscarriage
Official title: Oral Dydrogesterone Treatment During the First Trimester of Pregnancy in Women With Recurrent Miscarriage: A Double-Blind, Prospectively Randomized, Placebo-Controlled, Parallel Group Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Recurrent Miscarriage
Keywords: Pregnancy
Immunology
Unexplained recurrent miscarriage
Lead sponsor: Abbott
Sponsor class: INDUSTRY
First posted: 2005-09-19
Enrollment: 71
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 38
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this clinical study is to demonstrate the shift from inflammatory cytokines to non-inflammatory cytokines in women suffering from habitual abortion treated with dydrogesterone (Duphaston).


Eligibility criteria: Inclusion Criteria

* Women with a history of idiopathic recurrent miscarriage, based on a documented history of at least three spontaneous consecutive miscarriages before 20 weeks gestation with the same partner Exclusion Criteria
* Any verifiable cause of the recurrent miscarriages apart from luteal phase defect (e.g. systemic lupus erythematosus \[SLE\], infections with chlamydia or mycoplasma)
* Any gynecological neoplasias or anatomical abnormalities that oppose pregnancy
* Concurrent infertility treatment/superovulation protocol

Primary outcomes:
measure: Cytokine ratio IFN/IL-10
timeFrame: 14 weeks treatment after diagnosed pregnancy (week of gestation 4 to 18)
Secondary outcomes:
measure: Exploratory analysis of pregnancy outcome by monitoring biochemical and clinical pregnancy parameters, weekly evaluation of serum progesterone
timeFrame: First trimester of pregnancy
Other outcomes:
Locations:
city: Vienna
country: Austria
facility: Site Reference ID/Investigator# 61182
city: Poznan
country: Poland
facility: Site Reference ID/Investigator# 61183
city: Szczecin
country: Poland
facility: Site Reference ID/Investigator# 61184
Study officials:
affiliation: Abbott Products
name: Guenter Krause, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT00804674: Pain Study Using Intermittent Bupivacain Injections After Breast Reconstruction With DIEP Flap
Official title: Improved Pain Relief Using Intermittent Bupivacain Injections at the Donor Site After Breast Reconstruction With Deep Inferior Epigastric Artery Perforator (DIEP) Flap
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Breast Reconstruction
Keywords: bupivacain
breast
reconstruction
diep
pain
postoperative
catheter
anesthesia
Lead sponsor: Oslo University Hospital
Sponsor class: OTHER
First posted: 2008-12-09
Enrollment: 47
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: patients are given bupivacain intermittent locally on the donor site after brest reconstruction with diep flap. The hypothesis was that this approach will reduce the need for rescue analgetic medication and pain perception within the three first days


Eligibility criteria: Inclusion Criteria:

* all patients planned to undergo reconstructive breast surgery with a DIEP

Exclusion Criteria:

* regular use of analgesics
* known allergic reaction to bupivacain
* bleeding disorders
* pregnancy

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Consultant at ullevaal university hospital
name: jørgen utvoll, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05973474: The Atherogenic Index of Plasma（AIP） in Patients With Atrial Fibrillation
Official title: Prognostic Value of the Atherogenic Index of Plasma（AIP）for Cardiovascular Outcomes in Patients With Atrial Fibrillation
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Atrium; Fibrillation
Lipid Metabolism Disorders
Cardiovascular Diseases
Event, Cardiac
Lead sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Sponsor class: OTHER
First posted: 2023-08-03
Enrollment: 5000
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients diagnosed with AF during hospitalization in our hospital.

Brief summary: The goal of this observational study is to learn about The Atherogenic Index of Plasma(AIP) in patients with atrial fibrillation(AF). The main questions it aims to answer are: (1)To investigate the correlation between AIP and the occurrence rate of AF. (2) To investigate the correlation between AIP and the occurrence rate of cardiovascular outcome events (MACE events, heart failure, embolism events) in patients with AF. Patients's clinical data including medical history, laboratory tests, and imageological examination will be collected and further analysed.

Detailed description: Baseline demographic data: age, gender, height, weight, systolic blood pressure, diastolic blood pressure, smoking habit, drinking habit, physical activity, fasting blood glucose, medication use (statins, ACEI/ARB, anticoagulant related drugs), basic medical history (hypertension, diabetes mellitus, coronary heart disease).

Eligibility criteria: Inclusion Criteria:

1. Atrial fibrillation was detected by electrocardiogram or 24-hour holter or portable electrocardiogram monitor;
2. age ≥18 years old;
3. "low-intermediate" risk group of AF cardioembolic stroke: male patients with CHA2DS2-VASc score 0-1 or female patients with CHA2DS2-VASc score 1-2

Exclusion Criteria:

1. patients with rheumatic heart disease, congenital heart disease, cardiomyopathy, hematological diseases, severe hepatic and renal insufficiency and connective tissue diseases;
2. Echocardiography showed valvular heart disease;
3. patients with transient atrial fibrillation secondary to reversible causes: hyperthyroidism, acute pulmonary embolism, recent surgery, acute myocardial infarction, etc.
4. severe carotid artery stenosis and intracranial artery stenosis;
5. AF patients with recent major surgery.
6. patients with serious lack of clinical data.

Primary outcomes:
measure: atrial fibrillation (AF)
timeFrame: 10 years
Secondary outcomes:
measure: major adverse cardiovascular events (MACEs)
timeFrame: 10 years
measure: heart failure
timeFrame: 10 years
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01133574: This is a Single Ascending Dose Tolerance Study
Official title: A Double-Blind, Randomized, Placebo Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profiles of SLV354 After Oral Dose Administration in Healthy Adult Male Subjects
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
Conditions: Cognition Disorders
Keywords: Healthy volunteers
SLV354
Phase I
SRDT
Lead sponsor: Abbott
Sponsor class: INDUSTRY
Collaborators: name: Quintiles, Inc.
First posted: 2010-05-31
Enrollment: 47
Sex: MALE
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a single rising dose tolerance (Part A) followed by a functional magnetic resonance imaging (Part B)

Detailed description: The Part A of this study is a parallel design followed in a second part by a cross-over design

Eligibility criteria: Inclusion Criteria

* BMI 18.0 to 28.0 kg/m2,
* systolic blood pressure 90-140 mmHg,
* diastolic blood pressure 50-90 mmHg,
* heart rate 50 100 beats/min (all inclusive),
* clinically normal safety ECG and laboratory results

Exclusion Criteria

* relevant disease,
* treated with SLV354 before

Primary outcomes:
measure: Safety and tolerability assessments including adverse events, clinical laboratory tests, ECG and vital signs (Part A)
timeFrame: 1 week after each dose level
measure: Safety and tolerability assessments including adverse events, clinical laboratory tests, ECG and vital signs (Part B)
timeFrame: 2 weeks after each dose
Secondary outcomes:
measure: Pharmacokinetic parameters (AUC and Cmax) after single ascending oral dosing of max. 8 doses of SLV354 ranging from 20 to 1250 mg (Part A)
timeFrame: 1 week after each dose level
measure: Pharmacodynamic variables (EEG, Cognitive tests, Questionnaires, plasma hormones ACTH / cortisol / TSH / T3 / T4) (Part A)
timeFrame: 1 week after each dose level
measure: Pharmacokinetic parameters (AUC and Cmax) after single oral dosing of 2-4 doses of SLV354 chosen (Part B)
timeFrame: 2 weeks after each dose
measure: Pharmacodynamic variables : Cognitive tests, Questionnaires, fMRI) (Part B)
timeFrame: 2 weeks after each dose
Other outcomes:
Locations:
city: London
country: United Kingdom
facility: Site Reference ID/Investigator# 62002
Study officials:
affiliation: Abbott
name: Beatrice Rendenbach-Mueller, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT00370786: Effect of Intravitreal Bevacizumab on Non -Age-Related Macular Degeneration (AMD) Related Choroidal Neovascularization (CNV)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Choroidal Neovascularization
Keywords: Choroidal neovascularization (CNV)
Bevacizumab
Non AMD
High myopia
angioid streaks
Ocular histoplasmosis
Idiopathic
Lead sponsor: Shahid Beheshti University of Medical Sciences
Sponsor class: OTHER
First posted: 2006-09-01
Enrollment: 31
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To evaluate the effect of bevacizumab for treatment of non-AMD choroidal neovascularization (CNV); eg:angioid streaks, ocular histoplasmosis, high myopia, idiopathic,etc


Eligibility criteria: Inclusion Criteria:

* Cases with subfoveal or juxtafoveal CNV due to a non-AMD related cause.

Exclusion Criteria:

* Evidence of AMD

Primary outcomes:
measure: Visual acuity
timeFrame: 6 months
Secondary outcomes:
measure: central macular thickness
timeFrame: 6 months
measure: leakage in fluorescein angiography
timeFrame: 6 months
Other outcomes:
Locations:
city: Tehran
country: Iran, Islamic Republic of
facility: Hamid Ahmadieh, MD
Study officials:
affiliation: Ophthalmic Research Center of Shaheed Beheshti Medical University
name: Hamid Ahmadieh, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00593086: Virtual Reality in Burn Pain Management
Official title: The Use of Virtual Reality Video Games to Control Procedural Pain During Burn Wound Care
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Burns
Pain
Keywords: wound care
Lead sponsor: United States Army Institute of Surgical Research
Sponsor class: FED
First posted: 2008-01-14
Enrollment: 26
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: To examine the safety and efficacy of Virtual Reality (VR) distraction therapy in burn patients experiencing severe procedural pain during wound care.

Detailed description: This is a prospective, randomized cross-over study of the safety and effectiveness of the use of a virtual reality distraction intervention to management procedural pain during burn wound care. Up to 20 subjects will be enrolled until 12 complete the study.

Eligibility criteria: Inclusion Criteria:

* 18 years or oler with thermal injury
* Understands English
* patient perception of previous wound care procedural pain is greater than 6 on a numeric pain scal of 0-10 where 0= no pain and 10=worst pain ever experienced
* ability to use a computer mouse or hit the space bar on a computer keyboard

Exclusion Criteria:

* unhealed burned wounds on face, neck or head
* history of severe susceptibility to motion sickness
* presence of open woun ds to the hands that cannot be covered with a dressing while operating the control button
* patients who report a feeling of anxiety or discomfort while viewing the Snow World software on a computer without the helmet

Primary outcomes:
measure: There will be a 20-50% reduction in pain while using Virtual Reality Games during burn wound care
timeFrame: 48 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Fort Sam Houston
country: United States
facility: USAISR
state: Texas
Study officials:
affiliation: United States Army Institute of Surgical Research
name: Christopher Maani, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Patterson DR, Hoffman HG, Weichman SA, Jensen MP, Sharar SR. Optimizing control of pain from severe burns: a literature review. Am J Clin Hypn. 2004 Jul;47(1):43-54. doi: 10.1080/00029157.2004.10401474. No abstract available.
Clinical trial NCT00167986: Study Evaluating Antibiotic Use in Reducing Vancomycin-Resistant Enterococci and ESBL Producing Escherichia Coli and Klebsiella Pneumoniae in Intensive Care
Official title: Antibiotic Intervention Trial in a Medical Intensive Care Unit to Reduce the Acquisition of Vancomycin-Resistant Enterococci and ESBL Producing Escherichia Coli and Klebsiella Pneumoniae.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Escherichia Coli Infections
Klebsiella Infections
Keywords: Bacterial Infections
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
Sponsor class: INDUSTRY
First posted: 2005-09-14
Enrollment: 480
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE

Brief summary: To determine whether the restriction of 3rd generation cephalosporins and carbapenems contribute to the reduction of intestinal colonization or infection with vancomycin-resistant enterococci (VRE) in a medical intensive care unit (MICU).


Eligibility criteria: Inclusion Criteria:

* All patients admitted to or transferred to the MICU.
* Patients 18 years of age or older.
* Provide written informed consent.

Exclusion Criteria:

* Patients known to be infected or colonized by VRE or ESBL-producing E.coli, K.pneumoniae.
* Patients who have hypersensitivity to penicillin.
* Any underlying conditions or diseases that will be ultimately fatal within 48 hours.
* Any concurrent condition or medication which would interfere with absorption or metabolism of study drugs.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Gyunggi-do
country: Korea, Republic of
Study officials:
affiliation: Wyeth is now a wholly owned subsidiary of Pfizer
name: Medical Monitor
role: STUDY_DIRECTOR
References:
Clinical trial NCT00297986: Evaluation of Different Interfaces for Noninvasive Positive Pressure Ventilation (NPPV)
Official title: Evaluation of Different Interfaces for NPPV
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Respiratory Failure
Healthy
Lead sponsor: Policlinico Hospital
Sponsor class: OTHER
First posted: 2006-03-01
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: healthy subjects

Brief summary: In this study the investigators aimed to study the ventilatory performance of different interfaces during NPPV delivering.

Detailed description: We will test the ventilatory performance in term of ventilatory pattern, muscle effort and gas exchange of different interfaces for NPPV.

Eligibility criteria: Inclusion Criteria:

* Adult healthy subjects

Exclusion Criteria:

* Barotrauma

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Milano
country: Italy
facility: Policlinico Hospital
Study officials:
affiliation: Policlinico Hospital
name: Davide Chiumello, MD
role: PRINCIPAL_INVESTIGATOR
References: